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Summary Timing of surgery in premenopausal patients with breast cancer remains controversial. Angiogenesis is essential for tumour
growth and vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. We aimed to determine whether the
study of VEGF in relation to the menstrual cycle could help further the understanding of this issue of surgical intervention. Fourteen
premenopausal women were recruited, along with three post-menopausal women, a woman on an oral contraceptive pill and a single male
subject. Between eight and 11 samples were taken per person, over one menstrual cycle (over 1 month in the five controls) and analysed for
sex hormones and VEGF165. Serum VEGF was significantly lower in the luteal phase and showed a significant negative correlation with
progesterone in all 14 premenopausal women. No inter-sample variations of VEGF were noted in the controls. Serum from both phases of the
cycle from one subject was added to MCF-7 breast cancercells; VEGF expression in the supematant was lower in the cells to which the luteal
phase serum was added. The lowering of a potent angiogenic cytokine in the luteal phase suggests a possible decreased potential for
micrometastasis establishment in that phase. This fall in VEGF may be an effect of progesterone and should be the focus of future studies.
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TIhe controversy of the timing of surgical intervention in
premenopausal breast cancer patients was initiated when Hrushesky
et al (1989). in a study of44 patients. observed a better survival for
tumours resected between days 7 and 20 of the menstrual cycle.
Various studies follox%ed. with differing results. though four major
studies have favoured the second half of the cycle. when the influ-
ence ofprogesterone predominates (Badwe et al. 1991; Senie et al.
1991: Veronesi et al. 1994: Goldhirsch et al. 1997).
Angiogenesis has been shown to be essential for both the
growth and metastasis ofmany solid tumours. with a large number
of the data resulting from studies of breast cancer. In the absence
of angiogenesis. a tumour will not grow beyond the size of 2-
3 mm (Gimbrone et al. 1972). Vascular endothelial growth factor
(VEGF) is one of the most potent angiogenic cytokines. for both
normal embryogenesis and tumour growth (Breoer et al. 1990:
Kim et al. 1993). Breast tumour VEGF directly correlates with
intratumoral microsessel density and. furthermore. has been
shown to be an independent indicator of nodal metastasis and
disease-free sunival (Toi et al. 1994).
Because VEGF plays an important role in tumour growth. we
aimed to determine whether the study of this cytokine in
premenopausal women could identify variations of VEGF within
the normal menstrual cycle and. thus. suggest why the timing of
surgery might influence the outcome ofbreast cancer.
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MATERIALS AND METHODS
Fourteen premenopausal women were recruited with no prior
history of any breast disorders. None had any significant medical
history. except one woman, who had ankylosing spondylosis.
Three groups of controls were included: three post-menopausal
women. one premenopausal woman on a low-dose oestrogen
combined oral contraceptive pill and one male subject. Informed
verbal consent was obtained from all subjects.
Blood samples were taken at 4-day intervals in both the subjects
and the controls. In the case of the premenopausal women, these
were taken from day 1 of one menstrual cycle through to day 1 of
the following cycle (8-11 samples per person). Two extra peri-
ovulatory samples were taken in four premenopausal women:
thus. a total of 123 samples were taken from the premenopausal
women. 65 in the follicular phase and 58 in the luteal phase. The
controls had samples taken over a period of 1 month on the
following days - 1. 5. 9. 13. 17. 21. 25 and 29 (eight samples per
control): thus. a total of40 control samples were obtained from the
five controls. The serum was separated and stored at -80°C and
thawing was avoided until the assays were performed.
Simultaneous quantitative enzyme-hinked immunosorbent
assays (ELISAs) were performed for VEGF165 (R&D. UK).
follicle-stimulating hormone (FSH). luteinizing hormone (LH)
and progesterone (AxSYM system. Abbott Laboratories. USA).
Oestradiol was measured by radioimmunoassay (Coat-a-coat.
Diagnostic Products Corporation. USA).
Each menstrual cycle was divided into a follicular phase and a
luteal phase on the basis of an observed LH peak followed by a
progesterone level that fell within the luteal phase values of the
system used (. 10.4 nmol 1-1).
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Table 1 Median interquartile range and P-values for oestradiol. progesterone and VEGF in the follicular and luteal phases. Spearman's
correlation between VEGF and oestradiol, and VEGF and progesterone
No. of Oestradiol Progesone VEGF
samples median (IOR) median (IOR) median (IOR)
pmol 1-1 nmdl t1- pg mt-,
Folliar phase 65 191.0 0.8 206.5
(138.0-395.5) (0.6-1.6) (119.6-327.7)
Luteal phase 58 267.5 18.8 174.7
(151.3-362.8) (3.4-32.8) (83.1-239.8)
P-value (Mann-Whitney) 0.6 <0.0005 0.03
Spearman's correlation
P-value 0.37 0.03
(rho) (-0.081) (-0.193)
The sianificance between VEGF. oestradiol and progesterone
levels of the tx%o phases for all cycles was calculated using the
Mann-Whitney U-test for non-parametric data. Spearman's corre-
lation between these three variables was also calculated. A one-
way ANOVA (analysis of variance) was performed on the
controls.
The median day of establishment of the luteal phase was calcu-
lated. and statistics reperformed after dividing all the cycles into
'follicular' and luteal' phases on the basis ofthis day (day 17). i.e.
all values from day 1 to 16 were included in the follicular' group
and all values from day 17 onwards in the 'luteal' group.
MCF-7 breast cancer cells (1 x 100 000 cells per well) were
seeded in triplicate in RPMI medium with 5%7c fetal calf serum.
Serum from the follicular and luteal phases of the cycle of one
subject were each added in 5%7c concentration on two occasions to
a triplicate group of wells. Two sets of serum taken approximately
2 weeks apart from the control subject on the oral contraceptive
pill were also added to two sets of wells. After 4 days of growth.
the resultant supernatant was collected from each of the 12 wells
and assayed for VEGF165 by quantitative ELISA.
RESULTS
The menstrual cycles ranged from 26 to 35 days in length (median
28 days). AH cycles were found to be ov-ulatoryv that is. each
showed an LH surge followedby an appropriate mid-luteal peak of
progesterone (>16.7 nmol 1-1. reference range ofAxSYM system).
VEGF levels in the luteal phase (median 174.7 pg ml') were
significantly lower than those of the follicular phase (median
206.5 pg ml-'). with a P-value of 0.03 at 95% significance lesel.
(Table 1. Figure 1). The fall of VEGF between the peaks of the
follicular and luteal phases in each subject was calculated. This
showed an average fall of53.2% for all cycles taken together with
a ranae of35.4-81.7%c.
Progyesterone levels were significantly higher in the luteal phase
than the follicular phase (P < 0.0005). which was consistent with
the expected normal ovulatory luteal function. A corresponding
significant negative correlation was found betxeen VEGF and
progesterone (P = 0.03). Oestradiol levels did not vary signifi-
cantly between the two phases (P = 0.6). though the follicular
phase levels were marginally higher. Again. these values corre-
sponded to the expected range of oestradiol in o-ulatory cycles.
Spearman's correlation showed no significance between VEGF
and oestradiol (P = 0.37) (Table 1).
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Figure 1 Post-menopausal control. VEGF (pg ml:- ) oestradiol
(pmol F -- --): progesterone (nmol Vt x 5:.)
A one-way ANOVA was performed on the 40 control samples
to detenrine whether any statistical significance existed among
the day-to-day levels of the three factors. i.e. oestradiol. proges-
terone and VEGF. This revealed no significant difference within
the groups for VEGF. oestradiol or progesterone on the sample
days. with P-values of 1.0. 0.99 and 0.86 respectively. Fiaure 2
represents the graph of a post-menopausal control.
On redefining the cycles on the basis ofthe median day ofestab-
lishment of the luteal phase as described. VEGF levels in the
luteal' phase (i.e. values from day 17 onwards) were significantly
lower than in the 'follicular' phase (values from day 1 to 16). The
median luteal' level was 171.9 pg ml-' (IQR 82.7-225.0)
compared with a median follicular' level of 215.6 pg ml.' (IQR
121.1-238.1). P = 0.009 (Mann-Whitney U-test).
Analysis of the supematant from the MCF-7 breast cancer cells
grown with serum from a subject and a control showed that the
VEGF levels in the wells to which serum from the luteal phase was
added were significantly lower than the levels from the cells grown
in serum from the follicular phase (mean VEGF of three samples
with luteal serum: 706.73 pg ml-': mean VEGF of samples with
follicular serum: 800.04 pg ml-l: P = 0.05. Mann-Whitney U-test).
The supematant from the wells to which control serum had been
added did not show any significant difference in VEGF expression
(mean VEGF: 638.06 p mlF vs. 634.11 pg ml-': P = 0.5 .
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Table 2 Distb of serum VEGF in 138 control subjects
n VEGF pg n*l Pake
nedn (OR) Mann-Whftry)
Men 66 171.4 (95.3-290.0)
Women 72 173.8 (92.5-252.5) 0.995
Men <50 years 44 171.4 (81.6-318.9
Men 250 years 22 179.1 (101.9-285.8) 0.89
Premenopausal 52 165.0 (88.2-236.3)
Post-menopausal 20 243.9 (128.5-425.6) 0.01
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Figure 2 Typical graph of
oesdtadl (pmol '; ----);
DISCUSSION
The importance of VE
evident. It is an indepei
and a direct, significa
VEGF and intratumorn
Although other cytokim
are as potent and, in add
relationship between td
blood vessel growth.
VEGF and its high-al
sively on the vascular e
found in the necrotic cc
tion of both. Recently,
VEGF up-regulation
cytokines (epidermal gr
(Pertovaaraetal, 1994;
(interleukin 6, interleuk
al, 1995; Li et al, 1995
(ras, v-raf, v-Srr) (Grul
Rak et al, 1995). This b
paracrine fashion, may
trolled in vivo prolifera
It has recently been
VEGF gene (Carmeliet
the flt-I (Fong et al, 1
result in early intraute
ability of the VEGF/VI
ment ofthe vascular sys
We have previously
increasing stage in colo
post-operative serum le,
Although the role of
diseases is being increa
cance ofcirculating VEI
lished with certainty. It
maintaining the integritr
al, 1992), but, this being
no significant daily van
in a healthy individual. I
.. ' ', in a quiescent endothelium a concentration of50 pg ml-' would be
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9 13 17 21 25 29 the endothelium had been pre-sensitized, then even lower levels
Days than these would be effective. Cancer patients have various growth
factors and cytokines in their circulation which are capable ofsuch
a premenopausal subject VEGF (pg m-; ); presensitization. Connolly et al (1989) showed that the initial step
progesterone (nmol h1 x5; . of endothelial cell division, i.e. thymidine incorporation, occurred
at VEGF concentrations of 20 pg ml' in bovine aortic endothelial
cells. Thus, the effect ofthe variations in serum VEGFnoted in our
study cannot be underesimated. We have shown that these changes
follow apredictable pattern and that the average peak difference in
~GF in cancer biology is now becoming the two halves of the cycle was over 50%, with VEGF values
ndent prognostic indicator in breast cancer ranging between 80 and 600 pg ml-' in the subject population.
nt correlation has been shown between This is the first study to have demonstraed acyclical variation in
al microvessel density (Toi et al, 1995). serum VEGF levels in relation to the phases ofthe menstrual cycle.
es have been shown to be angiogenic, none The importance ofthis finding is increased in the light ofthe recent
lition, it has been difficult to demonstrate a study by Holdaway et al (1997), which has shown that the hormone
eirangiogenic activity and the regulation of profile of the menstrual cycle is maintained in patients with breast
cancer. Thus, it is fair to extapolate these findings in normal
ffinity receptors, flt- 1 and KDR, act exclu- premenopausal women to those with breast cancer. We have shown
ndothelium, and hypoxia (e.g. such as that that all 14 subjects had significant lowering of their VEGF levels
-ntre of a tumour) causes major up-regula- under the progesterone curve of the luteal phase. As soon as the
a variety of unrelated mechanisms causing progesterone levels fell to the baseline values, serum VEGF once
have been identified, including other again began to rise. Furthermore. when serum from the same
rowth factor, transforming growth factor-5) woman belonging to different phases of the cycle was added to
Frank et al. 1995), inflammatory mediators breast cell cultures, all other factors remaining the same, a similar
in lIa and0, prostaglandin E2) (Ben-Av et lowering effectby higher levels ofprogesterone was seen on VEGF
i; Cohen et al. 1996) and some oncogenes levels. The addition of serum from an oral contraceptive user who
gel et al, 1995; Mukhopadhyay et al, 1995; did not show variations in oestradiol or progesterone levels did not
ias led to the belief that VEGF, acting in a result in any variations in VEGF expression. These findings
be the fmal common pathway of uncon- provide firther evidence that it is probably the high progesterone
tion (Ferrara, 1996). levels in the luteal phase that decrease VEGF expression.
shown that heterozygous mutations of the VEGF, being induced by inflammatory mediators, is known to
et al, 1996) and homozygous mutations of rise in conditions such as autoimmune arnhritis. This was reflected
995) or KDR (Shalabi et al, 1995) genes in the generally higher levels ofVEGF seen in the subject who had
mne death, demonstrating the indispens- exacerbation of ankylosing spondylosis during the cycle of this
EGF receptor system for normal develop- study, compared with the rest ofthe study group (median 533.3 vs.
stem. 175.6 pg ml-', P < 0.0005, Mann-Whitney test): but, even in this
shown that serum VEGF is elevated with subject, VEGF fell significantly during the luteal phase, only to
)rectal cancer (Kumar et al. 1998) and that rise sharply once progesterone levels returned to baseline values.
vels can predict oncological clearance. The three groups ofcontrols were chosen for two reasons: firstly
VEGF in tunmofigenesis and inflammatory to determine whether serum VEGFordinarily showed daily fluctu-
Lsingly studied and understood, the signifi- ations in a population that excluded premenopausal women and.
GF in the healthy adult remains to be estab- secondly, if not, whether the variations in premenopausal women
is believed that VEGF may have a role in could be attributed to hormonal variations, as these three control
y of the vascular endothelium (Jakeman et groups would not be expected to show any significant day-to-day
g a rather quiescent epithelium in the adult, changes in their hormonal profile. Indeed. as expected, no signifi-
iations in serum VEGF would be expected cant fluctuations in oestradiol or progesterone levels were noted,
Ferrara et al (1991) suggested that probably but, more importantly. no significant daily change in serum VEGF
British Joumal ofCancer(1998) 78(9), 1203-1207
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was detected (P = 1.0). This corroborated the evidence that the
VEGF changes in premenopausal women were probably hormone
dependent. In addition. serum VEGF in the three post-menopausal
wAomen was higher than in the premenopausal women. This was as
suggested in an earlier studv from our unit on 138 healthy controls
from the general population (66 men and 72 women). This studv
had shown that there was no significant difference between VEGF
levels in men (median 171.4 pg ml-') compared with those in
females (median 173.8 pg ml-': P = 0.99): however. there was a
sig,nificant difference between premenopausal (n = 52. median
VEGF 165 pg ml-') and post-menopausal women (n = 20. median
VEGF 243.9 pg ml: P = 0.01). No such difference was found
between the VEGF levels in males when acut-offpoint of50 years
(average agye of menopause) was used. i.e. men <50 years (n = 44.
median VEGF = 171.4 pg ml-') compared with men > 50 years
(n =22. median VEGF = 179.1 pg, ml-l' P = 0.89) (Table 2). These
data emphasize the point that the changes found in women are
unlikely to be attributable to a difference in age.
In a retrospective study. Badwe et al (1991) showed a signifi-
cantly better survival for premenopausal breast cancer patients
operated on in the second half of the cycle. The difference was as
significant as the presence or absence of lymph node metastases.
which is the most important prognostic indicator of breast cancer.
This difference was accentuated in small tumours that were lymph
node positive. Badwe et al hypothesized that lymph node-positive
disease would be expected to have a higher metastatic potential
because ofpreviously disseminated cells. These cells are under the
balancinc influence of v-arious factors. both inhibitory and stimu-
latory. produced by the tumour. The removal of the primary
tumour alters this balance. and the presence of unopposed
oestrogen may allow these micrometastases to multiply and
survive. whereas in the luteal phase they may perish. Folkman
(1971 ) has shown that tumour progression is angiogenesis depen-
dent. and has explained the various clinical time scales of metas-
tases presentation on the basis of angiogenesis-based tumour
dormancv. Folkman (1995) suggaests that the presentation of
metastases is dictated by the intensitv of angiogenesis that they
induce. Once the balance of negative and positive angliogenesis
factors is such that proangiogenic factors predominate. the
micrometastases switch to the angiogenic phenotype and grow.
VEGF is one of the key factors secreted by the tumour implicated
in the local micrometastasis milieu. It has been experimentally
shown that the administration of anti-VEGF antibodies and the
introduction of dominant negative VEGF receptors (to interfere
with VEGF signalling) result in reduction of tumour growth
(Millauer et al. 1994: Warren et al. 1995). Also. anti-VEGF anti-
bodies inhibit the development ofmetastasis even when the size of
the primary is similar to that of untreated animals with metastasis
(Melnyk et al. 1996) and serum VEGF is reduced following
tumour removal. suggesting that VEGF might function as an
endocrine endothelial factor in some populations of patients
(Yamamoto et al. 1996: Kumar et al. 1997).
Folkman's view of micrometastasis is now widely, accepted.
though in the context of breast cancer the contribution of the
sexual hormonal profile remains controversial. We believe that
VEGF expression may provide that link. The stimulatory role of
oestrogen in normal and neoplastic breast tissue has been shown in
multiple in vitro and in vi-o models. It has also been shown that
oestradiol causes up-regaulation of VEGF expression in human
endometrial cancer cell lines (Chamnock-Jones et al. 1993). and
that the pattern ofexpression of VEGF suggtests that it plays a role
in hormone-regulated anglogenesis (Shwveiki et al. 1993). Our
present in vivo and in vitro results indicate that progesterone may
be the factor causing down-regulation of VEGF Thus. the findinc
of a lower serum VEGF in the luteal phase would support both
Badwe's findings and Folkman's anaiogenesis hypothesis by
creating a lower potential for angiogenesis. and. thus. for estab-
lishment of metastases in this phase. It is possible that the high
levels ofVEGF in post-menopausal women are a reflection ofthis
protective effect ofprogesterone. i.e. even though there is insignif-
icant ovarian oestradiol produced post-menopausually: it may be
that even low levels of circulatincg extraovarian oestrogens. in the
absence of any significant progesterone. are able to accumulate in
an unopposed manner. resulting, in higher levels of serum VEGE
This is a factor that may be worth further study in the context of
the higher incidence ofbreast cancer in post-menopausal women.
By dividing each cycle on the basis of actual hormonal
measurements. we have removed the bias as to which phase the
recorded VEGF values belona. Interestingly, when the cycles were
divided on the basis of a median dav ofestablishment ofthe luteal
phase. the drop in levels of VEGF in the second half of the cycle
became more significant. This was so even though the women had
a wide ranae of individual cycle lengths. If further studies were to
support luteal phase intervention on the basis ofVEGF levels, then
this finding, would potentially preclude the need to routinely
perform preoperative hormone profiles. as surgery undertaken
beyond day 17 could be considered as being within a 'safe' period
ofthe cycle.
We have suggested a possible mechanism via which the
improved prognosis of breast cancer surgery in the luteal phase
may be explained. Further prospective clinical studies lookincg at
the effects ofoestrogen and progesterone on VEGF expression are
required to establish progesterone as the protective factor. This
would have immense implications not only in timing, surgical
intervention in premenopausal breast cancer patients. but also in
advancing the therapeutic options available for the disease.
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